News & Updates

Show Multimedia Only
Sotrovimab benefits select hospitalized COVID-19 patients
Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026 byAudrey Abella

In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.

Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026
Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
21 Jan 2026 byChristina Lau

Chinese patients with locally advanced or metastatic, EGFR-mutated, MET-amplified non-small-cell lung cancer (NSCLC) whose disease progressed on first-line (1L) EGFR tyrosine kinase inhibitor (TKI) therapy obtain progression-free survival (PFS) benefit from the all-oral combination of savolitinib plus osimertinib vs platinum-based doublet chemotherapy, interim results of the phase III SACHI trial have shown.

Savolitinib + osimertinib a potential option for Chinese patients with EGFR-mutated, MET-amplified NSCLC
21 Jan 2026